Baker's yeast as a tool for the development of antifungal drugs which target cell integrity - An update

Expert Opinion on Drug Discovery

Volumn 3, Issue 8, 2008, Pages 931-943

  Heinisch, Jürgen J ^a  

^a UNIVERSITY OF OSNABRÜCK   (Germany)

Author keywords

Bioinformatics; Cell wall integrity pathway; Genetic screens; Plasma membrane

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ESCULENTIN; FATTY ACID SYNTHASE INHIBITOR; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 ANTIBODY; NIKKOMYCIN Z; NYSTATIN; POLYPEPTIDE ANTIBIOTIC AGENT; RECOMBINANT ANTIBODY;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; CANDIDA ALBICANS; CELL WALL; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; ENZYME INHIBITION; FUNGAL GENETICS; FUNGAL STRAIN; FUNGUS MUTANT; HIGH THROUGHPUT SCREENING; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SACCHAROMYCES CEREVISIAE;

EID: 48749089501     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.8.931     Document Type: Review

References (83)

1. Yoneyama H, Katsumata R. Antibiotic resistance in bacteria and its future for novel antibiotic development. Biosci Biotechnol Biochem 2006;70:1060-75
2. Maor R, Shirasu K. The arms race continues: battle strategies between plants and fungal pathogens. Curr Opin Microbiol 2005;8:399-404
3. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980 - 1997. Clin Infect Dis 2001;33:641-7
4. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-63
5. De Lucca AJ. Harmful fungi in both agriculture and medicine. Rev Iberoam Micol 2007;24:3-13
6. Hedayati MT, Pasqualotto AC, Warn PA, et al. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 2007;153:1677-92
7. Strahl S, Heinisch JJ. Fungal cell wall biosynthesis: a view on biodiversity in fungi and application of '-omics'. Yeast 2007;24:217-9
8. Lesage G, Bussey H. Cell wall assembly in Saccharomyces cerevisiae. Microbiol Mol Biol Rev 2006;70:317-43
9. Klis FM, Mol P, Hellingwerf K, Brul S. Dynamics of cell wall structure in Saccharomyces cerevisiae. FEMS Microbiol Rev 2002;26:239-56
10. Heinisch JJ. Baker's yeast as a tool for the development of antifungal kinase inhibitors-Targeting protein kinase C and the cell integrity pathway. Biochim Biophys Acta 2005;1754:171-82
11. EUROSCARF. Available from: http://web.uni-frankfurt.de/fb15/mikro/ euroscarf/
12. Gorlach JM, McDade HC, Perfect JR, Cox GM. Antisense repression in Cryptococcus neoformans as a laboratory tool and potential antifungal strategy. Microbiology 2002;148:213-9
13. Giaever G, Chu AM, Ni L, et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature 2002;418:387-91
14. Roemer T, Jiang B, Davison J, et al. Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery. Mol Microbiol 2003;50:167-81
15. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol 2003;11:272-9
16. Gassner NC, Tamble CM, Bock JE, et al. Accelerating the discovery of biologically active small molecules using a high-throughput yeast halo assay. J Nat Prod 2007;70:383-90
17. Evans JM, Zaworski PG, Parker CN. A high throughput screen for inhibitors of fungal cell wall synthesis. J Biomol Screen 2002;7:359-66
18. Zaworski PG, Gill GS. Use of Saccharomyces cerevisiae expressing beta-galactosidase to screen for antimycotic agents directed against yeast cell wall biosynthesis and possible application to pathogenic fungi. Antimicrob Agents Chemother 1990;34:660-2
19. Anderson JB, Sirjusingh C, Parsons AB, et al. Mode of selection and experimental evolution of antifungal drug resistance in Saccharomyces cerevisiae. Genetics 2003;163:1287-98
20. Gupta SS, Ton VK, Beaudry V, et al. Antifungal activity of amiodarone is mediated by disruption of calcium homeostasis. J Biol Chem 2003;278:28831-9
21. Deutschbauer AM, Jaramillo DF, Proctor M, et al. Mechanisms of haploinsufficiency revealed by genuine-wide profiling in yeast. Genetics 2005;169:1915-25
22. Baetz K, McHardy L, Gable K, et al. Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action. Proc Natl Acad Sci USA 2004;101:4525-30
23. Pierce SE, Davis RW, Nislow C, Giaever G. Genome-wide analysis of barcoded Saccharomyces cerevisiae gene-deletion mutants in pooled cultures. Nat Protoc 2007;2:2958-74
24. Tong AH, Boone C. Synthetic genetic array analysis in Saccharomyces cerevisiae. Methods Mol Biol 2006;313:171-92
25. Arevalo-Rodriguez M, Pan X, Boeke JD, Heitman J. FKBP12 controls aspartate pathway flux in Saccharomyces cerevisiae to prevent toxic intermediate accumulation. Eukaryot Cell 2004;3:1287-96
26. Luesch H, Wu TY, Ren P, et al. A genome-wide overexpression screen in yeast for small-molecule target identification. Chem Biol 2005;12:55-63
27. Buurman ET, Andrews B, Blodgett AE, et al. Utilization of target-specific, hypersensitive strains of Saccharomyces cerevisiae to determine the mode of action of antifungal compounds. Antimicrob Agents Chemother 2005;49:2558-60
28. Lentze N, Auerbach D. The yeast two-hybrid system and its role in drug discovery. Expert Opin Ther Targets 2008;12:505-15
29. Khazak V, Golemis EA, Weber L. Development of a yeast two-hybrid screen for selection of human Ras-Raf protein interaction inhibitors. Methods Mol Biol 2005;310:253-71
30. Li XC, Jacob MR, Ding Y, et al. Capisterones A and B, which enhance fluconazole activity in Saccharomyces cerevisiae, from the marine green alga Penicillus capitatus. J Nat Prod 2006;69:542-6
31. Niimi M, Wada S, Tanabe K, et al. Functional analysis of fungal drug efflux transporters by heterologous expression in Saccharomyces cerevisiae. Jpn J Infect Dis 2005;58:1-7
32. Tiligada E. Chemotherapy: induction of stress responses. Endocr Relat Cancer 2006;13(Suppl 1):S115-24
33. Menacho-Marquez M, Murguia JR. Yeast on drugs: Saccharomyces cerevisiae as a tool for anticancer drug research. Clin Transl Oncol 2007;9:221-8
34. Gitler AD. Beer and bread to brains and beyond: can yeast cells teach us about neurodegenerative disease? Neurosignals 2008;16:52-62
35. Heinisch JJ, Lorberg A, Schmitz HP, Jacoby JJ. The protein kinase C-mediated MAP kinase pathway involved in the maintenance of cellular integrity in Saccharomyces cerevisiae. Mol Microbiol 1999;32:671-80
36. Krcmery V, Kalavsky E. Antifungal drug discovery, six new molecules patented after 10 years of feast: why do we need new patented drugs apart from new strategies? Recent Patents Anti Infect Drug Disc 2007;2:182-7
37. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008;61(Suppl 1):i19-30
38. Straede A, Corran A, Bundy J, Heinisch JJ. The effect of tea tree oil and antifungal agents on a reporter for yeast cell integrity signalling. Yeast 2007;24:321-34
39. Rodriguez-Pena JM, Diez-Muniz S, Nombela C, Arroyo J. A yeast strain biosensor to detect cell wall-perturbing agents. J Biotechnol 2008;133:311-7
40. Jain P, Akula I, Edlind T. Cyclic AMP signaling pathway modulates susceptibility of candida species and Saccharomyces cerevisiae to antifungal azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother 2003;47:3195-201
41. Hurtado-Guerrero R, van Aalten DM. Structure of Saccharomyces cerevisiae chitinase 1 and screening-based discovery of potent inhibitors. Chem Biol 2007;14:589-99
42. Willer T, Valero MC, Tanner W, et al. O-mannosyl glycans: from yeast to novel associations with human disease. Curr Opin Struct Biol 2003;13:621-30
43. Lommel M, Bagnat M, Strahl S. Aberrant processing of the WSC family and Mid2p cell surface sensors results in cell death of Saccharomyces cerevisiae O-mannosylation mutants. Mol Cell Biol 2004;24:46-57
44. Prill SK, Klinkert B, Timpel C, et al. PMT family of Candida albicans: five protein mannosyltransferase isoforms affect growth, morphogenesis and antifungal resistance. Mol Microbiol 2005;55:546-60
45. Olson GM, Fox DS, Wang P, et al. Role of protein O-mannosyltransferase Pmt4 in the morphogenesis and virulence of Cryptococcus neoformans. Eukaryot Cell 2007;6:222-34
46. Zhou H, Hu H, Zhang L, et al. O-Mannosyltransferase 1 in Aspergillus fumigatus (AfPmt1p) is crucial for cell wall integrity and conidium morphology, especially at an elevated temperature. Eukaryot Cell 2007;6:2260-8
47. Lengeler KB, Tielker D, Ernst JF. Protein-O-mannosyltransferases in virulence and development. Cell Mol Life Sci 2008;65:528-44
48. Daum G, Tuller G, Nemec T, et al. Systematic analysis of yeast strains with possible defects in lipid metabolism. Yeast 1999;15:601-14
49. DiDomenico B. Novel antifungal drugs. Curr Opin Microbiol 1999;2:509-15
50. Hong SY, Oh JE, Kwon M, et al. Identification and characterization of novel antimicrobial decapeptides generated by combinatorial chemistry. Antimicrob Agents Chemother 1998;42:2534-41
51. Vanden Bossche H, Engelen M, Rochette F. Antifungal agents of use an animal health -Chemical, biochemical and pharmacological aspects. J Vet Pharmacol Ther 2003;26:5-29
52. Laakso JA, Raulli R, McElhaney-Feser GE, et al. CT2108A and B: New fatty acid synthase inhibitors as antifungal agents. J Nat Prod 2003;66:1041-6
53. Dickson RC, Sumanasekera C, Lester RL. Functions and metabolism of sphingolipids in Saccharomyces cerevisiae. Prog Lipid Res 2006;45:447-65
54. Koo JC, Lee B, Young ME, et al. Pn-AMP1, a plant defense protein, induces actin depolarization in yeasts. Plant Cell Physiol 2004;45:1669-80
55. Morton CO, Hayes A, Wilson M, et al. Global phenotype screening and transcript analysis outlines the inhibitory mode(s) of action of two amphibian-derived, alpha-helical, cationic peptides on Saccharomyces cerevisiae. Antimicrob Agents Chemother 2007;51:3948-59
56. Brogden KA. Antimicrobial peptides: pore farmers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005;3:238-50
57. Aerts AM, Francois IE, Cammue BP, Thevissen K. The mode of antifungal action of plant, insect and human defensins. Cell Mol Life Sci 2008; doi: 10.1007/s00018-008-8035-0
58. Ramamoorthy V, Zhao X, Snyder AK, et al. Two mitogen-activated protein kinase signalling cascades mediate basal resistance to antifungal plant defensins in Fusarium graminearum. Cell Microbiol 2007;9:1491-506
59. Gamberi T, Cavalieri D, Magherini F, et al. An integrated analysis of the effects of Esculentin 1-21 on Saccharomyces cerevisiae. Biochim Biophys Acta 2007;1774:688-700
60. Hohmann S. Osmotic stress signaling and osmoadaptation in yeasts. Microbiol Mol Biol Rev 2002;66:300-72
61. Meyer V. A small protein that fights fungi: AFP as a new promising antifungal agent of biotechnological value. Appl Microbiol Biotechnol 2008;78:17-28
62. Monk BC, Niimi K, Lin S, et al. Surface-active fungicidal D-peptide inhibitors of the plasma membrane proton pump that block azole resistance. Antimicrob Agents Chemother 2005;49:57-70
63. Masman MF, Rodriguez AM, Raimondi M, et al. Penetratin and derivatives acting as antifungal agents. Eur J Med Chem 2008; doi: 10.1016/ j.ejmech.2008.02.019
64. Munoz A, Lopez-Garcia B, Marcos JF. Studies on the mode of action of the antifungal hexapeptide PAF26. Antimicrob Agents Chemother 2006;50:3847-55
65. Levin DE. Cell wall integrity signaling in Saccharomyces cerevisiae. Microbiol Mol Biol Rev 2005;69:262-91
66. Matthews RC, Burnie JP. Human recombinant antibody to HSP90: a natural partner in combination therapy. Curr Mol Med 2005;5:403-11
67. Buttner S, Eisenberg T, Herker E, et al. Why yeast cells can undergo apoptosis: death in times of peace, love, and war. J Cell Biol 2006;175:521-5
68. Phillips AJ, Crowe JD, Ramsdale M. Ras pathway signaling accelerates programmed cell death in the pathogenic fungus Candida albicans. Proc Natl Acad Sci USA 2006;103:726-31
69. Fardeau V, Lelandais G, Oldfield A, et al. The central role of PDR1 in the foundation of yeast drug resistance. J Biol Chem 2007;282:5063-74
70. Youle M. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother 2007;60:1195-205
71. Jungwirth H, Kuchler K. Yeast ABC transporters - a tale of sex, stress, drugs and aging. FEBS Lett 2006;580:1131-8
72. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother 2006;50:2892-4
73. Cruz MC, Cavallo LM, Gorlach JM, et al. Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol Cell Biol 1999;19:4101-12
74. Byrne KP, Wolfe KH. Consistent patterns of rate asymmetry and gene loss indicate widespread neofunctionalization of yeast genes after whole-genome duplication. Genetics 2007;175:1341-50
75. Gaughran JP, Lai MH, Kirsch DR, Silverman SJ. Nikkomycin Z is a specific inhibitor of Saccharomyces cerevisiae chitin synthase isozyme Chs3 in vitro and in vivo. J Bacteriol 1994;176:5857-60
76. Uhl MA, Biery M, Craig N, Johnson AD. Haploinsufficiency-based large-scale forward genetic analysis of filamentous growth in the diploid human fungal pathogen C.albicans. EMBO J 2003;22:2668-78
77. Hogan DA, Vik A, Kolter R. A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Mol Microbiol 2004;54:1212-23
78. Koziol S, Zagulski M, Bilinski T, Bartosz G. Antioxidants protect the yeast Saccharomyces cerevisiae against hypertonic stress. Free Radic Res 2005;39:365-71
79. Martinez LR, Casadevall A. Cryptococcus neoformans cells in biofilms are less susceptible than planktonic cells to antimicrobial molecules produced by the innate immune system. Infect Immun 2006;74:6118-23
80. Breger J, Fuchs BB, Aperis G, et al. Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog 2007;3:e18
81. Huang J, Zhu H, Haggarty SJ, et al. Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. Proc Natl Acad Sci USA 2004;101:16594-9
82. Zewail A, Xie MW, Xing Y, et al. Novel functions of the phosphatidylinositol metabolic pathway discovered by a chemical genomics screen with wortmannin. Proc Natl Acad Sci USA 2003;100:3345-50
83. Mukhopadhyay A, Weiner H. Delivery of drugs and macromolecules to mitochondria. Adv Drug Deliv Rev 2007;59:729-38